Chardan analyst Gbola Amusa upgraded Adverum Biotechnologies to Buy from Neutral with a price target of $20, up from $10, after the company reported new interim clinical data from the OPTIC phase 1 study of its gene therapy ADVM-022 in treatment-experienced patients with wet AMD. While the investment debate will be about balancing the "vastness of the market opportunity" for a one-time gene therapy against the likelihood that ADVM-022 efficacy is not repeated and the likelihood the low-grade inflammation derailing the program, Amusa said he is "not able to ignore the opportunity."